公开(公告)号：US20210106607A1

公开(公告)日：2021-04-15

申请号：US17065242

申请日：2020-10-07

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： MASATO YOSHIKAWA ,  Morihisa Saitoh ,  Taisuke Kato ,  Yayoi Nakayama ,  Tomohiro Seki ,  Yasuo Nakagawa ,  Yusuke Tominari ,  Masaki Seto ,  Yusuke Sasaki ,  Masanori Okaniwa ,  Tsuneo Oda ,  Akito Shibuya ,  Kosuke Hidaka ,  Zenyu Shiokawa ,  Shumpei Murata ,  Atsutoshi Okabe ,  Yoshihisa Nakada ,  Michiyo Mochizuki ,  Brian Scott Freeze ,  Taisuke Tawaraishi ,  Yasufumi Wada ,  Paul D. Greenspan

IPC: A61K31/7084 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02 ,  A61K47/68 ,  A61K31/7076

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US12171777B2

公开(公告)日：2024-12-24

申请号：US18310467

申请日：2023-05-01

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masato Yoshikawa ,  Morihisa Saitoh ,  Taisuke Kato ,  Yayoi Nakayama ,  Tomohiro Seki ,  Yasuo Nakagawa ,  Yusuke Tominari ,  Masaki Seto ,  Yusuke Sasaki ,  Masanori Okaniwa ,  Tsuneo Oda ,  Akito Shibuya ,  Kosuke Hidaka ,  Zenyu Shiokawa ,  Shumpei Murata ,  Atsutoshi Okabe ,  Yoshihisa Nakada ,  Michiyo Mochizuki ,  Brian Scott Freeze ,  Taisuke Tawaraishi ,  Yasufumi Wada ,  Paul D. Greenspan

IPC: A61K31/7084 ,  A61K31/7076 ,  A61K47/68 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US11666594B2

公开(公告)日：2023-06-06

申请号：US17065242

申请日：2020-10-07

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masato Yoshikawa ,  Morihisa Saitoh ,  Taisuke Kato ,  Yayoi Nakayama ,  Tomohiro Seki ,  Yasuo Nakagawa ,  Yusuke Tominari ,  Masaki Seto ,  Yusuke Sasaki ,  Masanori Okaniwa ,  Tsuneo Oda ,  Akito Shibuya ,  Kosuke Hidaka ,  Zenyu Shiokawa ,  Shumpei Murata ,  Atsutoshi Okabe ,  Yoshihisa Nakada ,  Michiyo Mochizuki ,  Brian Scott Freeze ,  Taisuke Tawaraishi ,  Yasufumi Wada ,  Paul D. Greenspan

IPC: A61K31/7084 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02 ,  A61K47/68 ,  A61K31/7076

CPC classification number: A61K31/7084 ,  A61K31/7076 ,  A61K47/6807 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I):




wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US10774083B2

公开(公告)日：2020-09-15

申请号：US16333296

申请日：2017-09-14

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takaharu Hirayama ,  Yasuhiro Hirata ,  Yusuke Tominari ,  Naoki Iwamura ,  Yusuke Sasaki ,  Moriteru Asano ,  Terufumi Takagi ,  Masanori Okaniwa ,  Shinichi Imamura

IPC: C07D401/04 ,  C07D401/14 ,  C07D473/28 ,  C07D405/14 ,  C07D413/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D473/40 ,  C07D519/00 ,  A61P35/00 ,  A61K31/506 ,  A61K31/444 ,  A61K31/4439 ,  C07D473/00 ,  C07D473/32 ,  A61K31/5377 ,  A61K31/501 ,  A61K31/52 ,  A61P43/00 ,  A61K31/437 ,  C12N9/99

Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US09890145B2

公开(公告)日：2018-02-13

申请号：US15137161

申请日：2016-04-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masato Yoshida ,  Kazuaki Takami ,  Yusuke Tominari ,  Zenyu Shiokawa ,  Akito Shibuya ,  Yusuke Sasaki ,  Tony Gibson ,  Terufumi Takagi

IPC: C07D401/14 ,  C07D487/04 ,  C07D417/14 ,  C07D487/10 ,  A61P37/00 ,  C07D403/14 ,  A61K31/4155 ,  C07D413/14 ,  C07D401/04 ,  C07D409/14 ,  C07D405/14 ,  A61K9/06 ,  A61K9/20 ,  A61K9/48 ,  C07D403/04 ,  C07D471/04 ,  C07D471/10 ,  C07D491/107 ,  C07D495/04

CPC classification number: C07D413/14 ,  A61K9/06 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/4858 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D495/04

Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US09751885B2

公开(公告)日：2017-09-05

申请号：US14435085

申请日：2013-10-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Naoki Tomita ,  Daisuke Tomita ,  Yusuke Tominari ,  Shinichi Imamura ,  Shinji Morimoto ,  Takuto Kojima ,  Masashi Toyofuku ,  Yasushi Hattori ,  Tomohiro Kaku ,  Mitsuhiro Ito

IPC: C07D487/04 ,  C07C255/58 ,  C07C255/60 ,  C07D231/40 ,  C07C317/40 ,  C07C237/30 ,  C07C237/38 ,  C07C237/40 ,  C07C255/29 ,  A61K45/06 ,  C07D309/14 ,  C07D319/18 ,  C07D413/12 ,  C07D241/12 ,  C07D417/12 ,  C07D261/14 ,  C07D207/12 ,  C07D285/135 ,  C07D211/58 ,  C07D295/135 ,  C07D213/40 ,  C07D207/46 ,  C07D213/36 ,  C07D223/12 ,  C07D231/38 ,  C07D241/18 ,  C07D265/36 ,  C07D277/38 ,  C07D333/20 ,  C07D405/12 ,  C07D471/04 ,  C07D513/04

CPC classification number: C07D487/04 ,  A61K45/06 ,  C07C237/30 ,  C07C237/38 ,  C07C237/40 ,  C07C255/29 ,  C07C255/58 ,  C07C255/60 ,  C07C317/40 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07D207/12 ,  C07D207/46 ,  C07D211/58 ,  C07D213/36 ,  C07D213/40 ,  C07D223/12 ,  C07D231/38 ,  C07D231/40 ,  C07D241/12 ,  C07D241/18 ,  C07D261/14 ,  C07D265/36 ,  C07D277/38 ,  C07D285/135 ,  C07D295/135 ,  C07D309/14 ,  C07D319/18 ,  C07D333/20 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D513/04

Abstract: The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R1, R2 and R3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R2 and R3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.

公开(公告)号：US10980825B2

公开(公告)日：2021-04-20

申请号：US16185258

申请日：2018-11-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masato Yoshikawa ,  Morihisa Saitoh ,  Taisuke Kato ,  Yayoi Nakayama ,  Tomohiro Seki ,  Yasuo Nakagawa ,  Yusuke Tominari ,  Masaki Seto ,  Akito Shibuya ,  Kosuke Hidaka ,  Zenyu Shiokawa ,  Yoshihisa Nakada ,  Michiyo Mochizuki

IPC: A61K31/7084 ,  A61K31/7076 ,  A61K47/68 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US20190192549A1

公开(公告)日：2019-06-27

申请号：US16185258

申请日：2018-11-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： MASATO YOSHIKAWA ,  Morihisa Saitoh ,  Taisuke Kato ,  Yayoi Yoshitomi ,  Tomohiro Seki ,  Yasuo Nakagawa ,  Yusuke Tominari ,  Masaki Seto ,  Yusuke Sasaki ,  Masanori Okaniwa ,  Tsuneo Oda ,  Akito Shibuya ,  Kosuke Hidaka ,  Zenyu Shiokawa ,  Shumpei Murata ,  Atsutoshi Okabe ,  Yoshihisa Nakada ,  Michiyo Mochizuki ,  Brian Scott Freeze ,  Taisuke Tawaraishi ,  Yasufumi Wada ,  Paul D. Greenspan

IPC: A61K31/7084 ,  A61P35/00 ,  A61K47/68 ,  A61K31/7076

CPC classification number: A61K31/7084 ,  A61K31/7076 ,  A61K47/6807 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US20210137962A9

公开(公告)日：2021-05-13

申请号：US16185258

申请日：2018-11-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masato Yoshikawa ,  Morihisa Saitoh ,  Taisuke Kato ,  Yayoi Yoshitomi ,  Tomohiro Seki ,  Yasuo Nakagawa ,  Yusuke Tominari ,  Masaki Seto ,  Akito Shibuya ,  Kosuke Hidaka ,  Zenyu Shiokawa ,  Yoshihisa Nakada ,  Michiyo Mochizuki

IPC: A61K31/7084 ,  A61P35/00 ,  A61K47/68 ,  A61K31/7076

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US10800754B2

公开(公告)日：2020-10-13

申请号：US16332993

申请日：2017-09-14

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takaharu Hirayama ,  Yasuhiro Hirata ,  Yusuke Tominari ,  Naoki Iwamura ,  Yusuke Sasaki ,  Moriteru Asano ,  Terufumi Takagi ,  Masanori Okaniwa ,  Masato Yoshida ,  Shinichi Imamura

IPC: C07D401/04 ,  C07D401/14 ,  C07D407/14 ,  C07D409/14 ,  C07D417/14 ,  A61P35/00

Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.